Sanofi and Seagen Ink Deal to Work on Cancer Targets

Sanofi and Seagen have sealed a joint agreement to develop antibody drug conjugates for up to three cancer targets, the first of which has already been selected.

The collaboration will combine Sanofi’s monoclonal antibody technology and Seagen’s antibody drug conjugate technology and will target tumor cells that express a specific protein.

Under the agreement, the two companies will fund global development activities and will share profits equally. Sanofi will pay Seagen an undisclosed amount for each chosen target.